Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|77|3-4|192-196

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.3-4, 2009-09, pp. : 192-196

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 72, Iss. 1-2, 2007-11 ,pp. : 58-63

Karger

Access to resources Recommend Favorite

Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

By  

Oncology, Vol. 80, Iss. 1-2, 2011-06 ,pp. : 70-75

Karger

Access to resources Recommend Favorite

A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI

By  

Oncology, Vol. 88, Iss. 3, 2014-11 ,pp. : 164-172

Karger

Access to resources Recommend Favorite

A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 317-322

Karger

Access to resources Recommend Favorite

Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 326-332

Karger

Access to resources Recommend Favorite